High-glucose-based peritoneal dialysis solution induces the upregulation of VEGF expression in human peritoneal mesothelial cells: The role of pleiotrophin

Liu,Jia; Wu,Xia; Liu,Yanchun; Xu,Yaguang; Huang,Yuhan; Xing,Changying; Wang,Xiaoyun

doi:10.3892/ijmm.2013.1491

High-glucose-based peritoneal dialysis solution induces the upregulation of VEGF expression in human peritoneal mesothelial cells: The role of pleiotrophin

Authors:
- Jia Liu
- Xia Wu
- Yanchun Liu
- Yaguang Xu
- Yuhan Huang
- Changying Xing
- Xiaoyun Wang
View Affiliations

Affiliations: Department of Nephrology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: September 12, 2013 https://doi.org/10.3892/ijmm.2013.1491
Pages: 1150-1158

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of a high-glucose-based peritoneal dialysis solution (HGPDS) on the expression of pleiotrophin (PTN) and vascular endothelial growth factor (VEGF) in human peritoneal mesothelial cells (HPMCs) and the mechanisms through which fluvastatin (Flu) protects the peritoneal membrane in continuous ambulatory peritoneal dialysis (CAPD). HPMCs were cultured with HGPDS, Flu (10-8‑10-6 mol/l) and PTN (10‑30 nmol/l). The expression of PTN and VEGF was examined at the mRNA and protein level. To define the role of PTN in the regulation of VEGF expression, HPMCs were cultured with HGPDS in the presence or absence of the blocking peptide of PTN. The signaling pathways involved in PTN synthesis induced by HGPDS were also characterized. The phenotypic characteristics of HPMCs were observed under a light microscope. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetry and the mRNA and protein expression of PTN, VEGF and ERK1/2 was assessed by RT‑PCR and the western blot analysis, respectively. Following incubation with HGPDS for 48 h, the morphology of the HPMCs changed from a typical cobblestone‑like appearance to a fibroblast‑like phenotype. The same alteration in the morphology of the HPMCs also occurred following incubation with 20 nmol/l PTN. Flu (10-6 mol/l), GSK650394 [a competitive inhibitor of serum/glucocorticoid-regulated kinase 1 (SGK1), 10-5 mol/l] and PD98059 (a competitive inhibitor of ERK1/2, 10-5 mol/l) improved the negative changes in cell morphology induced by HGPDS. The results of MTT assay revealed that the reduction in HPMC viability occurred in the groups treated with HGPDS and this reduction was partially restored by Flu, GSK650394 and PD98059. A significant improvement in cell viability, which had been decreased by HGPDS, was observed following treatment with Flu (10-6 mol/l), PD98059 (10-5 mol/l) or GSK650394 (10-5 mol/l) (P<0.05). Compared with the control, the mRNA and protein expression of PTN and VEGF significantly increased in the HPMCs treated with HGPDS (P<0.05). GSK650394 and PD98059 significantly decreased the high mRNA and protein expression levels of PTN and VEGF induced by HGPDS (P<0.05) and Flu had the same inhibitory effect as GSK650394 and PD98059 in a dose‑dependent manner (P<0.05). The mRNA and protein expression of VEGF increased following the incubation of HPMCs with 20 nmol/l PTN. By contrast, the mRNA and protein expression levels of VEGF in the HPMCs decreased in the presence of the blocking peptide of PTN. The results from the present study indicated that HGPDS increased the expression of PTN and VEGF in the HPMCs, and this increase was attenuated by Flu, GSK650394 and PD98059. The protein expression of phosphorylated ERK1/2 (p-ERK1/2) was decreased by GSK650394 in the HPMCs treated with HGPDS. Taken together, the protective effects of Flu in HPMCs may be partially achieved through the SGK1‑ERK1/2 signaling pathway.

View Figures

View References

1	He Z, Potter R, Li X and Flessner M: Stretch of human mesothelial cells increases cytokine expression. Adv Perit Dial. 28:2–9. 2012.PubMed/NCBI
2	Loureiro J, Aguilera A, Selgas R, et al: Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage. J Am Soc Nephrol. 22:1682–1695. 2011.
3	Mizutani M, Ito Y, Mizuno M, et al: Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Am J Physiol Renal Physiol. 298:F721–F733. 2010. View Article : Google Scholar : PubMed/NCBI
4	Yokoi H, Kasahara M, Mori K, et al: Peritoneal fibrosis and high transport are induced in mildly pre-injured peritoneum by 3,4-didexoxyglucosone-3-ene in mice. Perit Dial Int. 33:143–154. 2013. View Article : Google Scholar : PubMed/NCBI
5	Heimbürger O, Waniewski J, Werynski A, et al: Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int. 38:495–506. 1990.
6	Davies SJ, Phillips L, Naish PF and Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 12:1046–1051. 2001.PubMed/NCBI
7	Plum J, Hermann S, Fussholler A, et al: Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int Suppl. 78:S42–S47. 2001. View Article : Google Scholar : PubMed/NCBI
8	Zweers MM, de Waart DR, Smit W, et al: Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med. 134:124–132. 1999. View Article : Google Scholar : PubMed/NCBI
9	Zweers MM, Struijk DG, Smit W and Krediet RT: Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med. 137:125–132. 2001. View Article : Google Scholar : PubMed/NCBI
10	Milner PG, Li YS, Hoffman RM, et al: A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence. Biochem Biophys Res Commun. 165:1096–1103. 1989. View Article : Google Scholar : PubMed/NCBI
11	Rauvala H: An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J. 8:2933–2941. 1989.PubMed/NCBI
12	Deuel TF, Zhang N, Yeh HJ, et al: Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch Biochem Biophys. 397:162–171. 2002. View Article : Google Scholar : PubMed/NCBI
13	Kohashi T, Tateaki Y, Tateno C, et al: Expression of pleiotrophin in hepatic nonparenchymal cells and preneoplastic nodules in carbon tetrachloride-induced fibrotic rat liver. Growth Factors. 20:53–60. 2002. View Article : Google Scholar : PubMed/NCBI
14	Henger A, Kretzler M, Doran P, et al: Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int. 65:904–917. 2004. View Article : Google Scholar : PubMed/NCBI
15	Yokoi H, Kasahara M, Mori K, et al: Pleiotrophin triggers inflammation and increased peritoneal permeability leading to peritoneal fibrosis. Kidney Int. 81:160–169. 2012. View Article : Google Scholar : PubMed/NCBI
16	Jorres A and Witowski J: PD membrane: biological responses to different PD fluids. Contrib Nephrol. 150:48–53. 2006. View Article : Google Scholar : PubMed/NCBI
17	Vrtovsnik F, Coester AM, Lopes-Barreto D, et al: Induction of chronic kidney failure in a long-term peritoneal exposure model in the rat: effects on functional and structural peritoneal alterations. Perit Dial Int. 30:558–569. 2010. View Article : Google Scholar : PubMed/NCBI
18	De Vriese AS, Mortier S and Lameire NH: Glucotoxicity of the peritoneal membrane: the case for VEGF. Nephrol Dial Transplant. 16:2299–2302. 2001.PubMed/NCBI
19	Szeto CC, Wong TY, Lai KB, et al: The role of vascular endothelial growth factor in peritoneal hyperpermeability during CAPD-related peritonitis. Perit Dial Int. 22:265–267. 2002.PubMed/NCBI
20	Kong Y, Bai PS, Nan KJ, et al: Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer. Int J Colorectal Dis. 27:287–298. 2012. View Article : Google Scholar : PubMed/NCBI
21	Saad S, Stevens VA, Wassef L, et al: High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney Int. 68:985–997. 2005. View Article : Google Scholar : PubMed/NCBI
22	Waldegger S, Barth P, Raber G and Lang F: Cloning and characterization of a putative human serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume. Proc Natl Acad Sci USA. 94:4440–4445. 1997.
23	Firestone GL, Giampaolo JR and O’Keeffe BA: Stimulus-dependent regulation of serum and glucocorticoid inducible protein kinase (SGK) transcription, subcellular localization and enzymatic activity. Cell Physiol Biochem. 13:1–12. 2003. View Article : Google Scholar
24	Lang F and Cohen P: Regulation and physiological roles of serum- and glucocorticoid-induced protein kinase isoforms. Sci STKE. 2001:re172001.PubMed/NCBI
25	Waerntges S, Klingel K, Weigert C, et al: Excessive transcription of the human serum- and glucocorticoid dependent kinase hSGK1 in lung fibrosis. Cell Physiol Biochem. 12:135–142. 2002. View Article : Google Scholar : PubMed/NCBI
26	Fillon S, Klingel K, Warntges S, et al: Expression of the serine/threonine kinase hSGK1 in chronic viral hepatitis. Cell Physiol Biochem. 12:47–54. 2002. View Article : Google Scholar : PubMed/NCBI
27	Roskoski R Jr: ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 66:105–143. 2012. View Article : Google Scholar : PubMed/NCBI
28	Zhu P, Ren M, Yang C, et al: Involvement of RAGE, MAPK and NF-κB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol. 21:123–129. 2012.
29	Vasan RS, Sullivan LM, Roubenoff R, et al: Inflammatory markers and the risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham heart study. Circulation. 107:1486–1491. 2003. View Article : Google Scholar : PubMed/NCBI
30	Yokota T, Utsunomiya K, Murakawa Y, et al: Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney Int Suppl. 71:S178–S181. 1999. View Article : Google Scholar : PubMed/NCBI
31	Hayashi M, Tapping RI, Chao TH, et al: BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase. J Biol Chem. 276:8631–8634. 2001. View Article : Google Scholar : PubMed/NCBI
32	Mizuno H and Nishida E: The ERK MAP kinase pathway mediates induction of SGK (serum- and glucocorticoid-inducible kinase) by growth factors. Genes Cells. 6:261–268. 2001. View Article : Google Scholar : PubMed/NCBI
33	Meng F, Yamagiwa Y, Taffetani S, et al: IL-6 activates serum and glucocorticoid kinase via p38alpha mitogen-activated protein kinase pathway. Am J Physiol Cell Physiol. 289:C971–C981. 2005. View Article : Google Scholar : PubMed/NCBI
34	Shelly C and Herrera R: Activation of SGK1 by HGF, Rac1 and integrin-mediated cell adhesion in MDCK cells: PI-3K-dependent and -independent pathways. J Cell Sci. 115:1985–1993. 2002.PubMed/NCBI
35	Prasad N, Topping RS, Zhou D and Decker SJ: Oxidative stress and vanadate induce tyrosine phosphorylation of phosphoinositide-dependent kinase 1(PDK1). Biochemistry. 39:6929–6935. 2000. View Article : Google Scholar : PubMed/NCBI